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Breast cancer is the most common cancer in most parts of the world and is a leading 
cause of death among women. Even though the incidence of the disease is increasing 
each year, early detection and improved treatments have increased the survival rates. 
Currently, only a few markers are used for either early diagnosis, treatment response or 
for survival of breast cancer. In this study, two-dimensional gel electrophoresis (2DGE) 
was used in the quest for new potential biomarkers for the disease. Breast cancer cell 
lines and normal breast cell line were used to optimize the conditions to produce the 
respective proteome maps. Fresh frozen samples representing tumor and adjacent normal 
tissues were then collected from patients who underwent breast surgery at HUKM, HKL 
and Hospital Putrajaya. A total of sixty samples representing tumor and adjacent normal 
tissues were collected from June 2005 to December 2006 and were screened using 
2DGE. Subsequently, 24 samples representing the different stages of infiltrating ductal 
carcinoma were used for further analysis using 17 cm IPG strips with 2 pH ranges 3-10 
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and 4-7, and the gels were analyzed using PDQuest 7.3 software. Several protein spots 
of interest were then excised and analyzed using MALDI-TOF spectrometer. Tumor 
rejection antigen (gp96), heat shock protein 90α, nucleosome assembly protein 1-like 1 
and opioid-binding cell adhesion molecule precursor were identified and found to be up-
regulated in breast cancer cell lines when compared to the normal breast cell line. 
Calreticulin, tumor rejection antigen (gp96), heat shock protein 60 and cytokine induced 
apoptosis inhibitor 1 were found to be up-regulated by 2 folds or more in tumor tissues 
when compared to the adjacent normal tissues. On the other hand, actin γ 2 and protein 
tyrosine phosphatase were found to be down-regulated in tumor tissues. Since 
Calreticulin, a calcium binding protein was more intense at different stages of the 
disease with its expression confirmed by Western blotting, it was chosen for further 
investigations. Quantitative RT-PCR with GAPDH as a house keeping gene was used to 
monitor the level of gene expression and to correlate the mRNA levels with calreticulin 
levels. In the samples that represent later stages of the disease, mRNA levels were found 
to be highly expressed in tumor tissues when compared to the adjacent normal tissues 
where in average more than 18 folds increase was observed. The mRNA level was also 
found to be decreased in stage IV sample where 12 folds increase was observed, 
indicating a possible role of calreticulin in the progression of the disease. In conclusion, 
the proteomics approaches were utilized in this study and was found to be valuable in 
the search for potential new biomarkers for breast cancer.  
. 
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Kanser payudara merupakan penyakit kanser yang paling banyak dihidapi sebahagian 
besar penduduk dunia dan menjadi penyebab utama kematian  di kalangan wanita.  
Walaupun insiden penyakit ini meningkat setiap tahun, namun pengesanan awal dan 
peningkatan dalam bidang pengubatan telah berjaya meningkatkan kekal hidup pesakit.  
Buat masa ini, hanya beberapa penanda yang digunakan pada penyakit kanser samada 
untuk diagnosis awal, mengesan tindak balas rawatan ataupun untuk menyelamatkan 
pesakit kanser payudara. Dalam kajian ini, elektroforesis gel dua-dimensi (2DGE) telah 
digunakan dalam usaha mencari penanda baru yang berpotensi untuk penyakit ini. 
Kultur sel kanser payudara dan sel normal telah digunakan untuk mengoptimumkan 
keadaan bagi menghasilkan peta proteom masing-masing kultur sel tersebut.  Sampel 
tisu segar beku dari tumor serta tisu normal yang berdekatan telah dikumpulkan dari 
pesakit-pesakit yang menjalani pembedahan di HUKM, HKL dan Hospital Putrajaya. 
Sejumlah enam puluh sampel telah berjaya dikumpulkan dari bulan Jun 2005 sehingga 
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Disember 2006, dan telah disaringkan dengan 2DGE. Seterusnya, 24 sampel mewakili 
peringkat yang berbeza merupakan jenis karsinoma duktal infiltrasi (IDC) telah 
dianalisis dengan lebih lanjut menggunakan 17cm lajur IPG pada dua tahap pH yang 
berlainan iaitu lingkungan 3-10 dan 4-7. Kesemua gel kemudian dianalisis dengan 
menggunakan perisian PDQuest 7.3. Beberapa bintik protein penting yang berjaya 
dicerap telah dikeluarkan dari gel dan dianalisis dengan menggunakan spektrometer 
MALDI-TOF. Antigen penghambat tumor (gp96), protein kejutan haba 90 alfa (HSP 
90α), himpunan nukleosom-1 menyerupai protein-1(NAP1L1) dan molekul pemula 
pelekat sel penambat opioid (OBCAM) telah dikenalpasti dan diekspresikan secara 
berlebihan dalam kultur sel kanser payudara, berbanding dengan kultur sel payudara 
normal. Kalretikulin, antigen penghambat tumor (gp96), protein kejutan haba 60 (HSP 
60), dan sitokin penghambatan aruhan apoptosis-1 (CIAPIN1) telah didapati juga 
diekspresikan secara dua kali ganda atau lebih berlebihan dalam tisu tumor berbanding 
dengan tisu normal yang berdekatan. Sebaliknya, aktin γ 2 dan enzim pemfosfatan 
tirosin protein (PTPs) pula telah didapati ekspresinya ditekan dalam tisu tumor. 
Memandangkan ekspresi kalretikulin, sejenis protein pengikat kalsium, adalah lebih 
ketara pada peringkat penyakit yang berbeza yang mana ekspresinya disahkan dengan 
western blotting dan ianya telah dipilih untuk analisis yang lebih mendalam. Kuantitatif 
RT-PCR dengan GAPDH sebagai gen kekal perumah telah digunakan sebagai kawalan 
aras ekspresi gen dan hubung kait antara aras mRNA dan aras protein. Pada sampel yang 
mewakili peringkat lewat penyakit ini, aras mRNA didapati diekspresikan amat tinggi 
pada tisu tumor berbanding tisu normal yang berdekatan di mana secara purata lebih 
daripada 18 kali ganda peningkatan didapati. Aras mRNA juga didapati menurun di 
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dalam sampel peringkat ke IV di mana peningkatan sebanyak 12 kali ganda didapati, 
menandakan adanya peranan yang munasabah bagi protein ini di dalam perkembangan 
penyakit tersebut.  Sebagai kesimpulan, pendekatan proteomik telah digunakan dalam 
kajian ini dan didapati berpotensi tinggi sebagai teknik dalam usaha mencari penanda 
yang baru untuk kanser payudara. 
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CHAPTER 1 
 
INTRODUCTION 
 
Breast cancer is the most frequent cancer in most parts of the world and is a leading 
cause of death among women. In the year 2002, 1.15 million new cases were estimated 
to have occurred globally (Parkin et al., 2005). Since more than half of the cases were 
reported from developed countries, it suggests that screening programs adopted in the 
these countries led to the detection of early invasive tumors (Jemal et al., 2007), which 
on the other hand would have been missed or detected at later stages in developing 
countries (Parkin et al., 2005). 
 
In 2008, a total of 184, 450 new cases from both sexes is estimated to be reported in the 
United States of America. Among them, 182, 460 new cases are expected be reported in 
females with 40,930 deaths (40,480 women and 450 men) (Jemal et al, 2008). It is also 
noted that breast cancer death rates have been decreasing gradually since 1990 due to 
early detection and improved treatments (ACS, 2007). 
 
In Malaysia, the national cancer registry in 2003 reported breast cancer as the most 
common cancer in females from all age groups above 15, and in all ethnic groups with 
3738 new cases. The overall age standardized incidence rate (ASR) was 46.2 per 
100,000 of population and 64.1 % of the cases were diagnosed in women between 40 
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and 60 years old. Chinese had the highest incidence followed by Indians and Malays 
with ASR of 59.7, 55.8 and 33.9 per 100,000 of population, respectively (NCR, 2004). 
 
However, the cultural and social beliefs of breast cancer in Malaysia are the most 
important contributors to the advanced stage of disease presentation (Hisham and Yip, 
2003). Also, in a study performed on patients from 1998 to 2001, the average size of 
tumor was 5.4 cm in diameter and Malay women had larger tumors and a later stage of 
disease at presentation than other ethnic groups. This was due to a strong confidence in 
traditional medicine, poverty and poor education, the negative perception of the disease 
together with fear and denial (Hisham and Yip, 2004).  
 
Current detection methods for breast cancer depend on mammography, but even though 
tumors detected by screening are significantly smaller than those non-screened ones, 
only 90% of tumors can be detected (Celis et al., 2005) and a tumor should be at least a 
few millimeters in size to be discovered, causing an important limitation to 
mammography (Hondermarck, 2003).  
 
After diagnosis, patients with primary breast tumors are often offered surgery followed 
by adjuvant therapy. Nevertheless, factors like tumor size, auxiliary lymph node 
involvement, steroid receptor status and metastasis to other organs affect the 5 year 
survival rates (Celis et al., 2005), in which lymph node negative patients have 
approximately 25 % recurrence rate while around 40% with lymph node positive will 
experience a relapse and they often die from metastatic tumor. Also, in the quest to 
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increase the survival rates among patients, systemic adjuvant therapy has led to the 
improvement in the prognosis of the disease but carried an important side effect of over-
treatment (Bergh and Holmquist, 2001). 
 
Consequently, there is a critical need to identify specific predictive and prognostic 
factors to determine the groups that can benefit from individual treatment and also 
diagnostic markers that will aid in detecting the disease at very early stages and thus 
increase the survival rates. 
 
Therefore, a better understanding of the changes that occur at the molecular and protein 
levels in breast cancer will facilitate the disease early detection and intervention by 
identifying new drug targets. The completion of human genome project has led to the 
rapid development in the technologies for the rapid and efficient analysis of the genes 
and their products, in which gene expression arrays and proteomics research particularly, 
are expected to provide important information to identify and characterize regulatory 
and functional networks of genes and proteins within cells (Celis et al., 2003) that are 
expected to accelerate the translation of basic research findings into clinical applications. 
 
Even though studies of protein properties and their relation with diseases started in the 
1970s, the field regained attention in the 1990s and a new name was applied 
“Proteomics” in 1995, that was defined as the large-scale characterization of the entire 
protein complement of a cell line, tissue, or organism (Kellner, 2000). A more inclusive 
definition was then introduced to combine the protein and genetic analyses (Pandey and 
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Mann, 2000) which has led to the emerging of different areas of research under 
proteomics, including protein-protein interaction studies, protein function, protein 
modifications, and protein location studies (Graves and Haystead, 2002). Accordingly, 
the involvement of different research disciplines such as biochemistry and molecular 
biology together with advances in mass spectrometry and bioinformatics resulted in the 
growth of proteomics as a powerful field towards the characterization of new markers 
and therapeutic targets (Hondermarck et al., 2002). 
 
In breast cancer research, cell lines are widely used experimental models to obtain a 
better understanding of the disease. There are a number of established cell lines such as 
MCF-7 and MDA-MB-231 that are well characterized and commonly used (Clarke et 
al., 1996). Even though breast cancer cell lines are easy to handle and have a high 
degree of homogeneity, they are mostly obtained from pleural effusions (Burdall et al., 
2003). Consequently, the results obtained from in vitro studies represent the aggressive 
tumors rather than primary lesions (Burdall et al., 2003). Thus, studying primary lesions 
of different tumor grades is more clinically relevant because most therapies are directed 
to these tumors. 
 
In this study, two dimensional gel electrophoresis (2DGE) coupled with mass 
spectrometric analysis was applied in search of new prognostic markers and therapeutic 
targets for breast cancer. Breast cancer cell lines, tumors and adjacent normal tissues 
surgically obtained from Malaysian patients diagnosed with primary breast cancer 
between 2005 and 2006 were used. 
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Thus, the objectives of this study are: 
 
1. To optimize the 2DGE conditions using breast cancer cell lines (MCF-7 and 
MDA-MB-231) and normal breast cell line (MCF-10A). 
2. To screen and select protein samples extracted from surgically obtained tumor 
and their adjacent normal tissues. 
3. To perform comparative differential analysis between tumor and normal tissues 
from infiltrating ductal carcinoma (IDC) samples. 
4. To confirm the expression of potential markers in IDC samples using Western 
blotting. 
5. To correlate the potential marker levels with their gene expression levels using 
real-time PCR. 
